



(51) International Patent Classification:

C07D 307/82 (2006.01) **A61P 3/04** (2006.01)
C07D 491/04 (2006.01) **A61P 3/10** (2006.01)
C07D 333/62 (2006.01) **A61P 9/00** (2006.01)
C07C 311/56 (2006.01) **A61P 9/10** (2006.01)
A61K 31/343 (2006.01) **A61P 11/00** (2006.01)
A61K 31/55 (2006.01) **A61P 11/06** (2006.01)
A61K 31/4162 (2006.01) **A61P 25/28** (2006.01)
A61P 1/04 (2006.01) **A61P 37/00** (2006.01)
A61P 1/16 (2006.01) **A61P 37/06** (2006.01)
A61P 3/00 (2006.01)

62/875,402

17 July 2019 (17.07.2019)

US

(71) Applicant: **ZOMAGEN BIOSCIENCES LTD** [GB/GB];
662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US).

(72) Inventors: **MOHAN, Raju**; 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US). **NUSS, John**; 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US). **HARRIS, Jason**; 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US). **YUAN, Shendong**; 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US).

(21) International Application Number:

PCT/IB2020/000634

(22) International Filing Date:

16 July 2020 (16.07.2020)

(25) Filing Language:

English












(26) Publication Language:

English

(30) Priority Data:

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS)



(57) Abstract: Described herein are N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds of formula (I) wherein R1 is formulae (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) and R2 is formulae (X) or (XI) as NLPR3 (pyrin domain-containing protein 3) modulators for the treatment of e.g. metabolic diseases (e.g. type 2 diabetes or obesity), liver diseases (e.g. NAFLD or cirrhosis), lung diseases (e.g. asthma or CORD), central nervous system diseases (e.g. Alzheimer's disease or multiple sclerosis), inflammatory or autoimmune diseases (e.g. rheumatoid arthritis or psoriasis), cardiovascular diseases (e.g. atherosclerosis or stroke). The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 67 to 90; examples 1 to 21; compounds 1 to 126; tables). An exemplary compound is e.g. N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl)-4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (Example 1; compound (5)).

[Continued on next page]



SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))